Drug intelligence / Profile preview

HS-10360

Development stage: Phase 1
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10360 is a small molecule drug developed by Jiangsu Hansoh Pharmaceutical. It is currently in Phase 1 clinical trials, primarily being investigated for the treatment of ulcerative colitis and other immune system and digestive system diseases. The available data indicate that it is administered orally, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy subjects. The precise mechanism of action or molecular target has not been publicly disclosed as of the latest updates[1][2][3][9].

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on HS-10360.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10360.

Explore the full profile